MPO and Parkinson disease: Jucaite et al. estimated the effects of treatment with the myeloperoxidase inhibitor AZD3241, comparing the Vt of [11C]-PBR28 at baseline and after 8 weeks of treatment in patients with PD while investigating neurodegeneration in the dopaminergic system undergoing PET with [18F]-FE- PE21.